|Year : 2014 | Volume
| Issue : 1 | Page : 90-97
Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression
Digvijay G Rana1, Varsha J Galani2
1 Department of Pharmacology, Sigma Institute of Pharmacy, Baroda, India
2 Department of Pharmacology, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Vallabh Vidyanagar, Gujarat, India
|Date of Web Publication||29-Sep-2014|
Varsha J Galani
Department of Pharmacology, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Vallabh Vidyanagar - 388 120, Gujarat
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: The effects of antidepressant treatments have traditionally been discussed primarily in terms of effects on noradrenergic and serotonergic systems. Multiple lines of investigation have also explored the role of dopaminergic systems in mental depression. Seed of Mucuna pruriens Linn. (DC) (Leguminoseae) is well-known with dopaminergic action and has several therapeutic applications in folk medicine in curing or managing a wide range of diseases including Parkinsonism. Aim: To elucidate the anti-depressent profile and possible dopaminergic modulating action of M. pruriens seeds in various experimental models of depression. Materials and Methods: In the present study, antidepressant effect of the hydroalcoholic extract of the M. pruriens seeds (MPE) (100 and 200 mg/kg, p.o.) was investigated in the Forced Swimming Test (FST), Tail Suspension Test (TST), and Chronic Unpredictable Mild Stress (CUMS) test in mice. Further, dopaminergic interaction of same doses of MPE in the FST and TST were checked by the administration of a haloperidol (0.1 mg/kg, i.p.) and bromocriptine (2 mg/kg, i.p.) on the 7 th day of MPE treatment. Effect of MPE on locomotor activity was also checked using actophotometer. Results: MPE produced a significant reduction of the immobility time in the FST and TST. Further, antidepressant action of MPE was significantly inhibited by haloperidol and potentiated by bromocriptine in the FST and TST. 21 days of MPE treatment produced protection in CUMS as indicated by a significant increase of sucrose intake of stressed mice. Locomotor activities of mice were not significantly changed after 1 h and 7 th day of the MPE treatment. Conclusion: The results of this study indicate that hydroalcoholic extract of MPE have antidepressant action, which may be mediated by an interaction with the dopaminergic system.
Keywords: Chronic mild stress test, forced swimming test, Mucuna pruriens, tail suspension test
|How to cite this article:|
Rana DG, Galani VJ. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. AYU 2014;35:90-7
|How to cite this URL:|
Rana DG, Galani VJ. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. AYU [serial online] 2014 [cited 2020 Oct 21];35:90-7. Available from: https://www.ayujournal.org/text.asp?2014/35/1/90/141949
| Introduction|| |
Depression is a disorder characterized by a broad range of symptoms, including altered mood and cognitive functions, and recurrent thoughts of death or suicide.  The World Health Organization (WHO) predicts that depression will become the second leading cause of premature death or disability worldwide by the year 2020.  The monoamine hypothesis of depression states that it is caused by functional deficit of monoamines (norepinephrine, serotonin and dopamine) at certain sites in the brain.  Previously study presented the first evidence for a dopaminergic dysfunction in depression.  Dopaminergic mesolimbic and mesocortical systems are involved in anhedonia and lack of motivation, two core symptoms of depression.  Because of the limitations of the antidepressant therapy, there has been renowned interest in medicinal plants, which have comparable efficacy to prescription medications with lesser side effects. Mucuna pruriens Linn. (DC) is a popular Indian medicinal plant commonly known as Cowitch, which has long been used in traditional Ayurvedic system of medicine for the management of a number of diseases. Roots are used in the treatment of nephropathy, strangury, dysmenorrhea, amenorrhea, elephantiasis, dropsy, neuropathy, ulcers, and fever and as febrifuge and tonic. Leaves are aphrodisiac, tonic, and are useful in ulcers, inflammation, helminthiasis, cephalalgia and general debility. Seeds are used in snakebite, sexual debility, cough, tuberculosis, impotence, rheumatic disorders, muscular pain, gonorrhea, sterility, gout, delirium, dysmenorrhea, diabetes, and cancer. , Several investigations have proposed that this plant possesses antiparkinsonian, antidiabetic, aphrodisiac, antioxidant, antineoplastic, antiepileptic, antimicrobial, anti-inflammatory, analgesic, and antipyretic activities.  A wide range of phytochemical constituents has been isolated from this plant. Presence of a large amount of L-dopa, alkaloids and a minor amount of 5-hydroxytryptamine have been reported in the seeds.  The powder of the seeds is clinically used for the management of hyperprolactinemia and Parkinson's disease, as it contains a high concentration of L-dopa a vital source of dopamine. , Also neuroprotective action of seeds of M. pruriens were showed to be due to restoration of the endogenous monoamine contents including dopamine in the substantia nigra  indicating dopaminergic action of M. pruriens seeds in the brain. In context to dopaminergic action of M. pruriens seeds and role of dopamine in the depression, the present study was designed to elucidate the anti-depressant profile and possible dopaminergic modulating action of M. pruriens seeds in various experimental models of depression.
| Materials and Methods|| |
Plant material and preparation of the hydroalcoholic extract of seeds of M. pruriens (MPE)
The authenticated dried seeds of M. pruriens Linn. were obtained from the Medicinal and Aromatic Plant Department, Anand Agriculture University, Anand, Gujarat, India. The seed material was powdered to mesh size 60 and extracted exhaustively with 50% ethanol using soxhlet apparatus. Crude (hydroalcoholic) extract was filtered and dried under reduced pressure at 40°C (yield-13% w/w of dried powdered material). Freshly prepared aqueous solution of the dried extract (MPE) in doses of 100 mg/kg, and 200 mg/kg were used for pharmacological study. 
Preliminary phytochemical screening
The qualitative chemical investigation of hydroalcoholic extract was carried out to check the presence of various phytoconstituents. 
Swiss mice (20-25 g) of either sex (total 150) bred in Central Animal House facility of the institute were used. These animals were housed under standard conditions, maintained on a 12 h light/dark cycle and had free access to food and water up to the time of experimentation. The animals were acclimatized to the laboratory environment 1 h before the experiments. Animals were randomly distributed into groups of 6 animals each. All experiments were conducted during the light period (08.00-16.00 h). All the protocols were approved by the Institutional Animal Ethics Committee (IAEC) and conducted according to the guidelines of Committee for the Purpose of Control and Supervision of Experiment on Animals (CPCSEA) (CPCSEA/IAEC/ARCP/09-10/07).
Imipramine hydrochloride (standard drug) was obtained as gratis sample from Psychotropic India Ltd., Faridabad. Haloperidol (Seranace® , RPG Life science, India) was used as dopamine receptor (D 2 ) antagonist. Bromocriptine mesylate (Proctinal® , GlaxoSmithKline, India) was used as dopamine receptor (D 2 ) agonist. Haloperidol was diluted in distilled water which was used for a vehicle of injection. Bromocriptine mesylate was dissolved in one drop of glacial acetic acid and made up to volume in distilled water. Imipramine was dissolved in 0.9% normal saline. Haloperidol (0.1 mg/kg, i.p.) and bromocriptine mesylate (2 mg/kg, i.p.) were administered for 7 days in groups of mice in Forced Swimming Test (FST) and Tail Suspension Test (TST). Imipramine (10 mg/kg, p.o.) as a standard was administered in positive control groups for 7 days.
Forced swimming test (FST)
Mice were divided in to ten groups, each group consisting of six animals. Groupings and treatment protocol are shown in [Table 1]. On 7 th day of the treatment, 1 h after MPE and imipramine or 30 min after haloperidol and bromocriptine administration, each animal was subjected to FST. Mice were made to swim individually in a polypropylene vessel (30 × 15 × 30 cm) with a water level of 15 cm at 25 ± 2°C. Two swim sessions were conducted, an initial 15 min pretest followed by a 5 min test 24 h later. The duration of immobility, characterized by complete cessation of swimming with the head just floating above water level was determined during the final 5 min period of test.  A decrease in the duration of immobility was indicative of an antidepressant effect.
Tail suspension test (TST)
TST was performed using another 10 groups of mice each consist of six animals. Groupings and treatment protocol are shown in [Table 1]. One hour after oral and 30 min after intraperitoneal administration, each animal was submitted to TST. Mice both acoustically and visually isolated were suspended on the edge of a table 50 cm above the floor by the adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 5 min period.  Animal was considered to be immobile when it did not show any movement of body and hung passively.
Chronic unpredictable mild stress (CUMS)
At the start of the experiment, mice were trained to consume 2% sucrose solution. Sucrose consumption was monitored throughout the experiment. After one week period of adaptation, sucrose solution intake baseline test was performed (two tests per 7 days) over a period of 18 days for all mice. This test involved a 3 h period of food and water deprivation, followed by offering of sucrose solution for 1 h. Intake was determined by weighing the bottles containing sucrose solution at the beginning and at the end of each test.  After this phase (18 days), one group of the 6 mice was housed under normal conditions (normal mice) and the other 24 mice were subjected to Chronic Unpredictable Mild Stress (CUMS). The stressor schedule was slightly modified from that used by Monleon et al.,  which include three 5 h periods of food and water deprivation, one 16 h period of water deprivation, three periods (3, 5, and 7 h) of intermittent illumination, three periods (5, 7, and 12 h) of 45° cage tilting, one 12 h period in a soiled cage (100 ml water in sawdust bedding) and three periods (7, 9, and 12 h) of low intensity stroboscopic illumination (150 flashes/min). The 14 stressors were scheduled in a semi-random order so that they were unpredictable for the animal. On average, two stressors were applied daily. The schedule was repeated weekly for 3 weeks. After 3 weeks of continuous exposure to the chronic mild stress, animals were divided into four matched subgroup. Group I served as stress control received normal saline (10 ml/kg, p.o.); groups II and III received oral treatment of MPE 100 and 200 mg/kg respectively; group IV served as a positive control received imipramine (10 mg/kg, p.o.) for 21 days. Sucrose intake was measured for each animal as mentioned above.
The locomotor activity of mice was measured using an actophotometer. The movement of the animal cuts off a beam of light falling on the photocell and a count was recorded and displayed digitally. Each mouse was placed individually in the actophotometer for 2 min for acclimatization and thereafter basal locomotor activity score was expressed in terms of total counts per 5 min. Mice were randomly divided into two group six mice in each group. One group was treated with MPE 100 mg/kg orally for 7 days. Other group was treated with MPE 200 mg/kg, orally for 7 days. Mice were individually placed again in the actophotometer after 1 h and 7 days of treatment for recording the locomotor activity score. 
Results were expressed as mean(s) ± SEM. The statistical significance of the difference between groups for the various treatments were determined by one-way analysis of variance (ANOVA) followed by Tukey's multiple range test. P < 0.05 or P < 0.001 was considered statistically significant as compared to control.
| Results|| |
Preliminary phytochemical screening
Phytochemical screening revealed the presence of alkaloid, carbohydrate, and aminoacid in the hydroalcoholic extract of MPE.
As shown in [Figure 1], significant (P < 0.001) and dose dependent reduction in the immobility time was observed with 7 days MPE (100 and 200 mg/kg, p.o.) treatment as compared to control. Similarly, positive control imipramine (10 mg/kg, p.o.) also produced antidepressant action as indicated by a significant reduction in the immobility time.
|Figure 1: Effect of hydroalcoholic extract of M. pruriens seeds on immobility time in forced swimming test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test; *P<0.05, **P<0.001 as compared to control|
Click here to view
Results of action of haloperidol and modification of haloperidol immobility time by MPE in FST are shown in [Figure 2]. Haloperidol (a dopamine antagonist) treatment (0.1 mg/kg, i.p.) group showed a significant rise in the immobility time as compared to control. When haloperidol (0.1 mg/kg, i.p.) was administered 30 min after the last dose of 7 days MPE treatments (100 and 200 mg/kg, p.o.) and subjected to FST, this dopaminergic antagonist showed significant and dose dependent reversal of anti-immobility action of MPE (100 and 200 mg/kg, p.o.) as compared to MPE treatment alone [Figure 2].
As shown in [Figure 3], bromocriptine (a dopamine agonist) treatment (2 mg/kg, i.p.) group showed significant anti-immobility action as compared to control. When bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produced significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone [Figure 3].
|Figure 2: Effect of hydroalcoholic extract of M. pruriens seeds (MPE) and its modulation by haloperidol in forced swimming test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test, **P<0.001 as compared to control; +P<0.05 as compared to MPE 100 mg/kg; ##P<0.001 as compared to MPE 200 mg/kg|
Click here to view
|Figure 3: Effect of hydroalcoholic extract of M. pruriens seeds (MPE) and its modulation by bromocriptine in the forced swimming test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test, **P<0.001 as compared to control; +P<0.05 as compared to MPE 200 mg/kg|
Click here to view
Results of TST are shown in [Figure 4]. There was significant (P < 0.001) and dose dependent reduction in the immobility time observed with 7 days MPE (100 and 200 mg/kg, p.o.) treatment as compared to control. Similarly, positive control imipramine (10 mg/kg, p.o.) showed anti-immobility activity, which further confirmed its antidepressant action.
|Figure 4: Effect of hydroalcoholic extract of M. pruriens seeds (MPE) on immobility time in the tail suspension test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test, *P<0.05, **P<0.001 as compared to control|
Click here to view
Results of action of haloperidol and modification of haloperidol immobility time by MPE in TST are shown in [Figure 5]. Haloperidol (a dopamine antagonist) treatment (0.1 mg/kg, i.p.) group caused a significant rise in the immobility time as compared to control. Haloperidol (0.1 mg/kg, i.p.) administration after 30 min of last dose of 7 days MPE treatments (100 and 200 mg/kg, p.o.) caused significant and dose dependent reversal of anti-immobility action of MPE.
As shown in [Figure 6], bromocriptine (a dopamine agonist) treatment (2 mg/kg, i.p.) group showed a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) showed significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone.
|Figure 5: Effect of hydroalcoholic extract of M. pruriens seeds (MPE) and its modulation by haloperidol in tail suspension test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test, **P<0.001 as compared to control; ++P<0.001 as compared to MPE 100 mg/kg; ##P<0.001 as compared to MPE 200 mg/kg|
Click here to view
|Figure 6: Effect of hydroalcoholic extract of M. pruriens seeds (MPE) and its modulation by bromocriptine in the tail suspension test. Each bar expressed as mean±SEM (n=6). One-way analysis of variance followed by Tukey's test, **P<0.001 as compared to control; ++P<0.001 as compared to MPE 100 mg/kg; ##P<0.001 as compared to MPE 200 mg/kg|
Click here to view
After the 1 week adaptation of sucrose solution, primary baseline value was determined by sucrose test. Then, mice were subjected to a chronic unpredictable stress schedule for 3 weeks. As shown in [Table 2], there was a significant decrease in the sucrose intake relative to control animals. Primary baseline value for sucrose consumption observed in normal control was 1.40 ± 0.02 g/kg body weight of mice. In the control stressed animals, significant reduction of sucrose intake was observed (1.02 ± 0.09) and remained throughout the study period as compared to normal control. In MPE treated mice (100 mg/kg, p.o.) sucrose intake was significantly increased (1.06 ± 0.04) after 17 days of treatment as compared to stress control (0.88 ± 0.05) mice and remained elevated for further 4 days of the test period. Similarly, higher dose of MPE treatment (200 mg/kg, p.o.) also, significantly increased sucrose consumption after 14 days (1.20 ± 0.08) as compared to stress control (0.88 ± 0.05). Positive control imipramine (10 mg/kg, p.o.) treated group also showed an increase in sucrose consumption after 14 days of treatment (1.25 ± 0.10) as compared to stress control (0.88 ± 0.05) group.
Acute oral administration of hydroalcoholic extract of MPE at the dose of 100 mg/kg did not show any significant changes in the locomotor activity of mice after 1 h (658.66 ± 7.38) as compared to baseline control (661.00 ± 7.01). While, 7 days treatment of MPE (100 mg/kg, p.o.) did not significantly change (657.33 ± 7.58) the locomotor activity of mice as compared to baseline control (661.00 ± 7.01). Similarly, higher tested dose of MPE (200 mg/kg, p.o.) did not show any significant changes in the locomotor activity after 1 h (570.5 ± 6.13) or after 7 days of treatment (569.33 ± 5.96) as compared to baseline control (572.33 ± 5.77).
| Discussion|| |
In the present investigation, antidepressant activity of the MPE was evaluated using various experimental models of depression. In the present study, 7 days treatment of hydroalcoholic extract of MPE in the dose of 100 mg/kg and 200 mg/kg (p.o.) in mice showed significant antidepressant activity in FST and TST, respectively. FST and TST are widely used to screen new antidepressant drugs. , Characteristic behavior scored in these tests is termed immobility, reflecting behavioral despair as seen in human depression. , It has been seen that TST is less stressful and has higher pharmacological sensitivity than FST. 
According to our result, the antidepressant like effect of MPE was significantly potentiated by bromocriptine (a dopamine D 2 receptor agonist) and reversed by haloperidol (a dopamine D 2 receptor antagonist) suggesting that antidepressant action of MPE mediated via interaction with dopaminergic system. Moreover, it should be pointed out that the antidepressant-like effect of MPE in the FST and TST do not seem to be associated with any stimulating locomotor activity, as at doses similar to that causing a marked antidepressant-like action did not affect spontaneous motor activity. MPE at the tested dose level did not produce any behavioral changes or motor dysfunction in the locomotor activity test after either the acute or repeated treatment. This result confirms the assumption that the antidepressant like effect of the MPE at the tested doses in the FST and TST are specific. Furthermore, the results observed with MPE treatment were largely comparable to imipramine, which suggests that MPE may produce a selective antidepressant effect.
In recent years, a number of lines of evidence have begun to shed light on the mechanisms of antidepressant drugs. One research work suggested that monoamine dopamine and especially the D 2 -like family of dopamine receptors might play a crucial role in mediating the action of antidepressant treatments.  There is also a report that dopamine D 2 receptor activation could reduce immobility time.  In the present study, the obtained results suggest the involvement of dopamine D 2 receptor agonistic nature of MPE in mediating its antidepressant action.
CUMS appears more suitable for studying the neurobiological basis of depression and the mechanisms of action of antidepressant drugs compared to acute stress models.  This paradigm has the advantage of excluding false positive effects caused by psycho-stimulant agents in acute stress based models.  The CUMS model of depression involves the presentation of a series of varied and unpredictable environmental stressors, such as food and water deprivation, wet cage and light-dark reversal. Following such exposure, animals have been reported to exhibit a persistent reduction in responsiveness to pleasurable stimuli, measured by a stress lead to decrease in consumption of sucrose solution in the test animals.  Chronic administration (21 days) of MPE could reverse the decrease in sucrose intake. Various studies indicated that of dopamine agonists , and antidepressants , produce similar effect. Taken together, the findings of the current study show that MPE displays a behavioral profile consistent with an antidepressant-like action. The efficacy of most herbal remedies is attributed to various active principles in combination. Results of phytochemical screening showed the presence of alkaloid, carbohydrate and aminoacids in the seeds. L-dopa is reported to be the main constituent mainly in seeds.  Therefore, the antidepressant activity can be attributed to dopaminergic action; however, the fact that MPE are more effective than L-dopa in Parkinson's disease in an animal model indicates a role for other active principles.  Therefore, present results suggest that intermittent administration of MPE as a dopamine agonist may merit clinical investigation as a novel strategy for the treatment of depression, particularly in patients with Parkinsonism More Details.
In conclusion, the present study provides scientific evidence that hydroalcoholic extract of MPE produces a specific antidepressant-like effect in acute and chronic models of depression which may be mediated by an interaction with the dopaminergic system.
| References|| |
|1.||Victor IR. Mental disorders. In: Kasper K, Braunwald E, editors. Harrison′s Principle of Internal Medicine. 16 th ed. New York: McGraw-Hill; 2005. p. 2551-2. |
|2.||WHO. WHO Director-General unveils new global strategies for mental health. Press Release. WHO/99-67, 1999. Available from: http://www.who.int/inf-pr-1999/en/pr99-67.html. [Last accessed on 2012 Oct 12]. |
|3.||Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 1988;319:348-53. |
|4.||Randrup A, Munkvad I, Fog R, Gerlach J, Molander L, Kjeilberg B, et al. Mania, depression and brain dopamine. In: Essman WB, Valzelli L, editors. Current Developments in Psychopharmacology. Vol. 2. New York: Spectrum Publications; 1975. p. 206-48. |
|5.||Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992;31:937-46. |
|6.||Warrier PK, Nambiar NP, Ramakutty C. Indian Medicinal Plants: A Compendium of 500 Species. Vol. 4. Madras: Orient Longman Ltd.; 1995. p. 68-72. |
|7.||Rastogi RP, Mehrotra BN. Compendium of Indian Medicinal Plants. Vol. 5. Lucknow: CDRI; 1994. p. 554. |
|8.||Sathiyanarayanan L, Arulmozhi S. Mucuna pruriens Linn.: A comprehensive review. Pharmacogn Rev 2007;1:157-62. |
|9.||Vaidya AB, Rajagopalan TG, Mankodi NA, Antarkar DS, Tathed PS, Purohit AV, et al. Treatment of Parkinson′s disease with the cowhage plant-Mucuna pruriens Bak. Neurol India 1978;26:171-6. |
|10.||Vaidya RA, Aloorkar SD, Sheth AR, Pandya SK. Activity of bromoergocryptine, Mucuna pruriens and L-dopa in the control of hyperprolactinaemia. Neurol India 1978;26:179-82. |
|11.||Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res 2004;18:706-12. |
|12.||Kokate CK. Practical Pharmacognosy. 4 th ed. New Delhi, India: Vallabh Prakashan; 1994. p. 107-9. |
|13.||Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36. |
|14.||Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985;85:367-70. |
|15.||Chen Y, Wang HD, Xia X, Kung HF, Pan Y, Kong LD. Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the chronic mild stress model of depression in mice. Phytomedicine 2007;14:523-9. |
|16.||Monleon S, D′Aquila P, Parra A, Simon VM, Brain PF, Willner P. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology (Berl) 1995;117:453-7. |
|17.||Dhir A, Kulkarni SK. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res Bull 2007;74:58-65. |
|18.||Willner P. The validity of animal model of depression. Psychopharmacology (Berl) 1984;83:1-16. |
|19.||Thierry B, Stéru L, Simon P, Porsolt RD. The tail suspension test: Ethical considerations. Psychopharmacology (Berl) 1986;90:284-5. |
|20.||Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007;61:145-53. |
|21.||Borsini F, Lecci A, Mancinelli A, D′Aranno V, Meli A. Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: Implication for antidepressant activity. Eur J Pharmacol 1988;148:301-7. |
|22.||Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987;93:358-64. |
|23.||Papp M, Moryl E, Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996;296:129-36. |
|24.||Richard M, Mariusz P, Willner P. Antidepressant like effect of dopamine agonist in an animal model of depression. Biol Psychiatry 1992;31:937-42. |
|25.||Yalcin I, Aksu F, Belzung C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur J Pharmacol 2005;514:165-74. |
|26.||Hussain G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson′s disease. Phytother Res 1997;11:419-23. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2]
|This article has been cited by|
||Possible anti-depressant effect of efavirenz and pro-depressive-like effect of voriconazole in specified doses in various experimental models of depression in mice
| ||Tejal K. Patel,Vandana B. Patel,Digvijay G. Rana |
| ||Pharmacological Reports. 2017; |
|[Pubmed] | [DOI]|
||Postpartum Lactation-Mediated Behavioral Outcomes and Drug Responses in a Spontaneous Mouse Model of Obsessive–Compulsive Disorder
| ||Swarup Mitra,McKenzie Mucha,Savanah Owen,Abel Bult-Ito |
| ||ACS Chemical Neuroscience. 2017; |
|[Pubmed] | [DOI]|
||Not only serotonergic system, but also dopaminergic system involved in albiflorin against chronic unpredictable mild stress-induced depression-like behavior in rats
| ||Jingjing Song,Xintong Hou,Xinyu Hu,Chengyu Lu,Chungang Liu,Juan Wang,Wei Liu,Lirong Teng,Di Wang |
| ||Chemico-Biological Interactions. 2015; 242: 211 |
|[Pubmed] | [DOI]|